United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research9/4/2026Negative
UTHR
United Therapeutics CorporationNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$20.91B
P/E Ratio
17.48
EPS
$27.89
Beta
0.56
52W High
$609.35
52W Low
$392.17
50-Day MA
$525.68
200-Day MA
$523.45
Dividend Yield
—
Profit Margin
41.60%
Forward P/E
16.18
PEG Ratio
2.22
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Fundamentals
| Revenue (TTM) | $3.15B |
| Gross Profit (TTM) | $2.72B |
| EBITDA | $1.50B |
| Operating Margin | 42.20% |
| Return on Equity | 19.30% |
| Return on Assets | 11.60% |
| Revenue/Share (TTM) | $72.85 |
| Book Value | $149.97 |
| Price-to-Book | 3.29 |
| Price-to-Sales (TTM) | 6.63 |
| EV/Revenue | 5.68 |
| EV/EBITDA | 10.68 |
| Quarterly Earnings Growth (YoY) | 13.40% |
| Quarterly Revenue Growth (YoY) | -1.90% |
| Shares Outstanding | $42.89M |
| Float | $39.21M |
| % Insiders | 2.00% |
| % Institutions | 100.00% |
Historical Volatility
HV 10-Day
27.80%
HV 20-Day
27.28%
HV 30-Day
24.77%
HV 60-Day
22.45%
HV Rank
43.3%
Volatility is currently expanding
Analyst Ratings
Consensus ($664.33 target)
3
Strong Buy8
Buy3
HoldLatest News
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
FDA accepts United Therapeutics' Tyvaso sNDA for an IPF label expansion, backed by TETON data showing improved lung function and reduced clinical worsening.
Zacks Investment Research9/3/2026Positive
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH
UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.
Zacks Investment Research8/28/2026Positive
United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the FDA and remains investigational for PAH. “Ralinepag has the potential to make an important difference.
Business Wire8/24/2026Neutral
UTHR Completes Phase III Tyvaso Study Enrollment for Expanded Label
United Therapeutics completes enrollment in its phase III study evaluating Tyvaso for an additional indication, PPF, with top-line results expected in the second half of 2027.
Zacks Investment Research8/18/2026Neutral
United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark
UTHR tops Q2 EPS estimates, misses revenues, while advancing Tyvaso and ralinepag programs that reshape future growth.
Zacks Investment Research8/6/2026Positive
United Therapeutics Q2 Earnings Call Highlights
United Therapeutics NASDAQ: UTHR reported second-quarter 2026 revenue of approximately $783 million, essentially flat from the first quarter, as competitive pressure affected sales of its nebulized TYVASO therapy. Company executives said they expect stronger performance in the second half of the year but did not reaffirm or update previous 2026 revenue-growth expectations.
MarketBeat8/5/2026Neutral
United Therapeutics Corporation (UTHR) Q2 2026 Earnings Call Transcript
United Therapeutics Corporation (UTHR) Q2 2026 Earnings Call Transcript
Seeking Alpha8/5/2026Neutral
United Therapeutics (UTHR) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research8/5/2026Positive
United Therapeutics (UTHR) Q2 Earnings Surpass Estimates
United Therapeutics (UTHR) came out with quarterly earnings of $7.27 per share, beating the Zacks Consensus Estimate of $6.82 per share. This compares to earnings of $6.41 per share a year ago.
Zacks Investment Research8/5/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on UTHR and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026